Wczytywanie kursów wyceny...
Prognoza
Średnia cena docelowa analityków wynosi 12,74 € (+52,39%). Mediana wynosi 12,74 € (+52,39%).
| Kupuj |
7 |
| Trzymaj |
0 |
| Sprzedaj |
0 |
Dyskusje w społeczności
Nie ma jeszcze dyskusji o tym aktywie.
Rozpocznij dyskusjęWiadomości Przejdź do aktualności
908 Devices focuses on handheld detection devices and strengthens financial profile
908 Devices announces a strategic focus on handheld chemical detectors intended to drive faster growth, improved margins and reduced cash burn. Revenue rose 23% in Q2 2026 to $16.1m, adjusted EBITDA loss for the quarter fell to below $2m, and the company reports $101.5m in cash with no debt. The 2026 revenue guidance was raised to $68–70m; recurring revenue is around 30% and is expected to grow further through the acquisition of NIRLab. 908 Devices highlights large market opportunities (opioid crisis, defense, border security) and an installed base of more than 4,100 devices with 700 customers in over 70 countries. » Więcej na de.investing.com
908 Devices reports 23% revenue growth in Q2 2026 and halves adjusted EBITDA loss
908 Devices posted Q2 2026 revenue of $16.1 million, up 23% year‑over‑year, driven by FTIR product shipments and U.S. state and local demand. Adjusted EBITDA loss narrowed to about $1.9 million, a roughly 50% improvement, while adjusted gross margin rose to ~57%. The company closed the NIRLAB acquisition, sold 35+ NIRLAB units with multiyear subscriptions, and secured a $6 million ProtectIR order for APAC. Cash and equivalents were $101.5 million with no debt, and full‑year revenue guidance was raised to $68–70 million, excluding potential AVCAD program upside. » Więcej na finance.yahoo.com
908 Devices focuses on handheld detection devices and reports solid financials
At the Growth Conference, 908 Devices presented a strategic shift away from medical technology toward handheld mass spectrometers for defense, law enforcement and public safety. The company has more than USD 100 million in liquidity and an adjusted EBITDA in the mid-single-digit millions, providing several years of financial runway. The product range spans the low-cost NIRLab to the flagship MX908; a new, more compact MX908 generation is planned for late 2026. Government grant programs and military projects such as AVCAD, together with growing international demand, are cited as the main growth drivers. » Więcej na de.investing.com
908 Devices accelerates transformation despite missed earnings expectation
908 Devices reported Q1 2026 revenue of $13.4 million (+14% y/y) and improved adjusted gross margin (57%) as well as adjusted EBITDA (-$2.5 million). EPS of -$0.32 missed estimates mainly due to a $6.4 million contingent consideration from acquisitions, while GAAP losses persist. The balance sheet is debt-free with $112 million in cash; the company is growing its installed base and recurring revenues, and the new VipIR device is expected to drive growth in 2026. For 2026, 908 Devices forecasts revenue of $67–70 million and an improvement in adjusted EBITDA to the mid-single-digit millions, but remains dependent on integration costs and the conversion to sustainable GAAP profitability. » Więcej na de.investing.com
908 Devices appoints Kola Otitoju as chief business & strategy officer
908 Devices has appointed Kola Otitoju to the newly created role of chief business & strategy officer; he will drive product and corporate strategy, business development, M&A and partnerships. Otitoju brings more than 25 years of experience in strategy, business development and P&L management, most recently serving as senior vice president at Repligen Corporation. The board granted him 110,193 RSUs and options on 146,789 common shares with an exercise price of $7.26; both awards vest over three years. The appointment comes after the stock rose 52% over the past year, though the company still reports a loss of $0.93 per share; the balance sheet is viewed as well capitalized/liquid. » Więcej na de.investing.com
Historyczne dywidendy Dywidendy
Wszystkie wskaźniki dywidendowe Wszystkie wskaźnikiDane finansowe spółki
| (EUR) | wrzesień 2026 | YoY |
|---|---|---|
| Przychody | 16,73 mln | 40,19% |
| Zysk brutto | 8,84 mln | 50,43% |
| Zysk netto | -4,04 mln | 68,18% |
| EBITDA | -4,09 mln | 65,22% |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 368,45 mln € |
Liczba akcji | 41,58 mln |
Maksimum/minimum z 52 tygodni | 12,14 € - 4,57 € |
| Dywidendy | Nie |
Beta | 0,63 |
C/Z (PE Ratio) | -15,46 |
PEG (PEG Ratio) | 0,01 |
C/WK (PB Ratio) | 2,67 |
C/S (PS Ratio) | 6,16 |
Profil spółki
908 Devices Inc., firma technologiczna będąca na etapie komercjalizacji, oferuje różnorodne, dedykowane urządzenia przenośne i stołowe do spektrometrii mas (Mass Spec), służące do badania nieznanych i niewidocznych materiałów w badaniach nauk przyrodniczych, bioprocesach, przemysłowej biotechnologii, kryminalistyce oraz pokrewnych rynkach. Produkty firmy obejmują MX908, przenośne, zasilane bateryjnie urządzenie Mass Spec przeznaczone do szybkiej analizy gazowych, ciekłych i stałych materiałów o nieznanym składzie; Rebel, niewielki analizator stołowy, który dostarcza informacji w czasie rzeczywistym o środowisku zewnątrzkomórkowym w bioprocesach; oraz rozwiązanie ZipChip, gotową do użycia, wysokorozdzielczą platformę separacyjną, która optymalizuje analizę próbek metodą Mass Spec. Firma działa w Ameryce, Europie, na Bliskim Wschodzie, w Afryce oraz w regionie Azji i Pacyfiku. Spółka została założona w 2012 roku i ma siedzibę główną w Bostonie w stanie Massachusetts.
| Nazwa | 908 DEVICES INC. DL-,001 |
| CEO | Kevin J. Knopp |
| Siedziba | Burlington,
ma Japonia |
| Strona internetowa | |
| Sektor | Usługi użyteczności publicznej |
| Branża | Sprzęt i usługi dla energetyki |
| Debiut giełdowy | 18.03.2010 |
| Pracownicy | 172 |
Symbole giełdowe
| Giełda | Symbol |
|---|---|
NASDAQ | MASS |